Abstracts events and patient withdrawals. Health care resource utilization was taken from published clinical trials measuring IOP-lowering of alternatives under evaluation and a local expert panel. Only direct medical costs were included in the model (drug acquisition, diagnostic procedures, ophthalmologist visits and treatment of withdrawals as second-line therapy). Drug acquisition cost data were obtained from official sources while the rest of costs data were taken from a national health care costs database. The perspective selected for this analysis was the Spanish National Health Service and the time horizon chosen was for three months, the time that patients were followed-up in most of the reported clinical trials. RESULTS: Cost per patient associated with the use of latanoprost was of €279 while the cost per patient secondary to use dorzolamide/timolol was of €281, with an incremental cost of €2 per patient treated. CONCLUSIONS: Despite Latanoprost acquisition is bigger, it is a more costeffective alternative than the fixed-combination of dorzolamide/timolol because produces similar clinical results with lower global associated costs. Therefore, latanoprost should be a therapeutic option to choose rather than dorzolamide/timolol in the treatment of open-angle glaucoma in Spain. 3 Cemka Eval, Bourg-la-Reine, Hauts de Seine, France OBJECTIVE: Endophthalmitis is the most severe infection following eye trauma (injury, surgery, injection, etc.). Medical costs and visual loss consequences are compared here. METHODS: A mailing announcing the creation of the National Endophtalmitis Survey was sent to all French ophthalmologists. A total of 424 replies were received and 346 (82%) were positive. A standardized anonymous questionnaire collected information on the operative conditions, endophthalmitis characteristics, treatments and clinical outcomes. The economic point of view was that of the French NHS and medical costs were extracted from the national Diagnosis Related Group database. Utility related to visual acuity loss was estimated from the literature (Brown). A €50,000/QALY threshold was used to assess cost-effective social value related to vision loss. A 5% discount rate was used. RESULTS: Information on 88 cases of endophthalmitis was collected. The mean age was 75.1 years and 44% were women. All patients were hospitalized, had bacteriological samples, and were treated with either systemic or intra-vitreal antibiotics. 25.3% had a vitrectomy. Complications were reported in 23.1% and most were mainly retinal detachments. 3 months after surgery, 29.4% of the eyes had a visual acuity (VA) less than 1/20 and in 57.4% VA was less than 5/10. The average endophthalmitis medical cost was €4125. The loss in utility was 0.203 on average (baseline VA fixed at 8/10). With a life expectancy of 5 years, the average discounted social value of endophthalmitis vision loss was €46,000. CONCLUSION: The social value attributable to vision loss subsequent to endophthalmitis is more than ten times higher than its medical cost. To evaluate the impact of best and worst eye visual acuity (VA) on the consumption of medical and non medical resources in patients with wet Age-Related Macular Degeneration (AMD). METHODS: This study conducted in France, Germany and Italy was cross-sectional with some data collected retrospectively. Patients with an exudative AMD form were included and were stratified into four levels of severity using two VA thresholds, 20/200 for the worst eye (WE) and 20/40 for the best eye (BE). In addition to demographics, AMD description and VA data, the medical and non-medical resources used for AMD reasons during the previous year were collected. Costs were assessed for each country according to a global payer perspective. An analysis of variance was performed on cost variables to estimate the impact of each eye adjusted by sex, age and country. RESULTS: 360 patients were included with a majority of females (60%). Mean age at inclusion was 77 years and time since diagnosis 2.3 years. 27% of patients had BE >20/40 and WE >20/200 and 25.5% BE <20/40 and WE <20/200. Total costs were €3923.5 with 64.5% of medical costs and 35.5% of nonmedical costs. Total costs increased with the AMD severity with a cost for the more severe group 1.5 times higher than for the less severe group. Costs were mainly associated with the BE VA. Medical cost was higher in France (€3714 versus €1900 on average in Germany and Italy). It increased slightly between less severe and more severe AMD. Non medical cost was significantly higher for patients with more severe disease and higher in Germany compared to the two other countries. CONCLUSION: This study shows the high impact of AMD on costs and the positive correlation between costs and AMD severity. Non medical costs of the most severe patients equaled medical costs. Patients with the following principal diagnoses were extracted: "purulent endophthalmitis", "other endophthalmitis", and "endophthalmitis associated with another disease". Two mean lengths of stay (LoS) were compared: the overall patient sample and the DRG-weighted estimate. Endophthalmitis costs were estimated as the sum of weighted average DRG costs plus length of stay multiplied by hospital variable costs. RESULTS: 1681 endophthalmitis cases were reported (age 66.7, 50% male). 1449 cases (86.2%) were in the public sector and 2.8% were ward transfers. A total of 221 (13.1%) had a vitrectomy, the most common endophtalmitis-related surgery. A total of 85 (5.1%) required a ward transfer and 4 (0.2%) died. The patient LoS was 7.6 days on average while the DRG weighted LoS was 4.3 days. Thus, the PMSI underestimates endophtalmitis LoS by 3.3 days. Mean
PEY13 COSTS AND CONSEQUENCES OF ENDOPHTHALMITIS: RESULTS FROM THE NATIONAL ENDOPHTALMITIS SURVEY
3 Cemka Eval, Bourg-la-Reine, Hauts de Seine, France OBJECTIVE: Endophthalmitis is the most severe infection following eye trauma (injury, surgery, injection, etc.) . Medical costs and visual loss consequences are compared here. METHODS: A mailing announcing the creation of the National Endophtalmitis Survey was sent to all French ophthalmologists. A total of 424 replies were received and 346 (82%) were positive. A standardized anonymous questionnaire collected information on the operative conditions, endophthalmitis characteristics, treatments and clinical outcomes. The economic point of view was that of the French NHS and medical costs were extracted from the national Diagnosis Related Group database. Utility related to visual acuity loss was estimated from the literature (Brown). A €50,000/QALY threshold was used to assess cost-effective social value related to vision loss. A 5% discount rate was used. RESULTS: Information on 88 cases of endophthalmitis was collected. The mean age was 75.1 years and 44% were women. All patients were hospitalized, had bacteriological samples, and were treated with either systemic or intra-vitreal antibiotics. 25.3% had a vitrectomy. Complications were reported in 23.1% and most were mainly retinal detachments. 3 months after surgery, 29.4% of the eyes had a visual acuity (VA) less than 1/20 and in 57.4% VA was less than 5/10. The average endophthalmitis medical cost was €4125. The loss in utility was 0.203 on average (baseline VA fixed at 8/10). With a life expectancy of 5 years, the average discounted social value of endophthalmitis vision loss was €46,000. CONCLUSION: The social value attributable to vision loss subsequent to endophthalmitis is more than ten times higher than its medical cost. To evaluate the impact of best and worst eye visual acuity (VA) on the consumption of medical and non medical resources in patients with wet Age-Related Macular Degeneration (AMD). METHODS: This study conducted in France, Germany and Italy was cross-sectional with some data collected retrospectively. Patients with an exudative AMD form were included and were stratified into four levels of severity using two VA thresholds, 20/200 for the worst eye (WE) and 20/40 for the best eye (BE). In addition to demographics, AMD description and VA data, the medical and non-medical resources used for AMD reasons during the previous year were collected. Costs were assessed for each country according to a global payer perspective. An analysis of variance was performed on cost variables to estimate the impact of each eye adjusted by sex, age and country. RESULTS: 360 patients were included with a majority of females (60%). Mean age at inclusion was 77 years and time since diagnosis 2.3 years. 27% of patients had BE >20/40 and WE >20/200 and 25.5% BE <20/40 and WE <20/200. Total costs were €3923.5 with 64.5% of medical costs and 35.5% of nonmedical costs. Total costs increased with the AMD severity with a cost for the more severe group 1.5 times higher than for the less severe group. Costs were mainly associated with the BE VA. Medical cost was higher in France (€3714 versus €1900 on average in Germany and Italy). It increased slightly between less severe and more severe AMD. Non medical cost was significantly higher for patients with more severe disease and higher in Germany compared to the two other countries. CONCLUSION: This study shows the high impact of AMD on costs and the positive correlation between costs and AMD severity. Non medical costs of the most severe patients equaled medical costs. Patients with the following principal diagnoses were extracted: "purulent endophthalmitis", "other endophthalmitis", and "endophthalmitis associated with another disease". Two mean lengths of stay (LoS) were compared: the overall patient sample and the DRG-weighted estimate. Endophthalmitis costs were estimated as the sum of weighted average DRG costs plus length of stay multiplied by hospital variable costs. RESULTS: 1681 endophthalmitis cases were reported (age 66.7, 50% male). 1449 cases (86.2%) were in the public sector and 2.8% were ward transfers. A total of 221 (13.1%) had a vitrectomy, the most common endophtalmitis-related surgery. A total of 85 (5.1%) required a ward transfer and 4 (0.2%) died. The patient LoS was 7.6 days on average while the DRG weighted LoS was 4.3 days. Thus, the PMSI underestimates endophtalmitis LoS by 3.3 days. Mean
PEY14 IMPACT OF VISUAL ACUITY ON MEDICAL AND NON-MEDICAL COSTS IN PATIENTS SUFFERING FROM WET AGE-RELATED MACULAR DEGEN-ERATION IN FRANCE, GERMANY AND ITALY

Benhaddi
PEY15 COST OF ENDOPHTHALMITIS: A NATIONWIDE APPROACH
